jeudi 9 avril 2020

Onco Actu du 9 avril 2020


1.1 BIOLOGIE - GÉNOME



Cancer Mutation in Dual Role [University of Freiburg]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



New Prognostic Tool Helps Leukemia Patients Plan for Cancer Treatment [ASH]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction [Genome Web]











4.10 DÉP., DIAG. & PRONO. - POUMON



MIT Team Develops Protease-Based Test for Early Detection of Lung Cancer [Genome Web]











4.12 BIOPSIES LIQUIDES



Esophageal Cancer Case Study Suggests Utility as Clinicians Explore Expanded Uses for Liquid Biopsy [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Pancreatic cancer blocked by disrupting cellular pH balance [Sanford Burnham Prebys]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings [Fierce Pharma]











Merck and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma [Merck]











FDA's new Keytruda review is a step for genetic medicine, immunotherapy [Biopharma Dive]











5.2.6 PHARMA - BIOTECH



Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs [Xconomy]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy [Pfizer]










6.15 LUTTE CONTRE LES CANCERS - COVID-19



Coronavirus and the Cancer Patient [NY Times]











Between Scylla and Charybdis — Oncologic Decision Making in the Time of Covid-19 [NEJM]